Lilly revenue surges 45% to $65.2B on Mounjaro/Zepbound; voluntary U.S. pricing pact risks offset

Lilly added Inluriyo, a new oncology product for ER-positive HER2-negative breast cancer with ESR1 mutations, to its marketed product portfolio. The product table includes compound patent protection through 2039 in major markets and data protection through 2030-2036 depending on territory. This expands Lilly's oncology franchise into a genetically-defined breast cancer segment.

The CLL/SLL indication for Jaypirca was revised to require only prior treatment with a covalent BTK inhibitor, removing the requirement for prior BCL-2 inhibitor therapy. This broadens the eligible patient population by allowing earlier-line use and simplifies the treatment history requirement, potentially expanding the addressable market.

The U.S. compound patent expiration date for Retevmo extended by one year from 2037 to 2038, likely reflecting a patent term adjustment or extension granted by the USPTO. This provides an additional year of exclusivity protection in the U.S. market before generic or biosimilar competition can enter.

Lilly disclosed four additional manufacturing expansion sites (Virginia, Texas, Alabama, Pennsylvania, and the Netherlands) beyond the baseline's six locations. This reflects significant capital investment to support anticipated demand for current and prospective products, particularly the high-growth incretin portfolio (Mounjaro/Zepbound). The geographic diversification also addresses supply-chain resilience.

LillyDirect evolved from a recently-launched U.S.-only platform for obesity/migraine/diabetes to an established multi-jurisdictional channel representing "a growing portion of our business in 2025." The current filing no longer describes it as "recent" and confirms it has achieved material scale. This reflects the platform's transition from pilot to meaningful revenue contributor and signals Lilly's commitment to direct-to-patient distribution as a strategic channel.

Lilly added new disclosure acknowledging intensified global competition, particularly from China and other emerging markets that have expanded R&D capabilities and are licensing products to multinationals, forming partnerships, and competing directly in major markets. This frames competition as a global innovation race requiring Lilly to access external innovation across geographies, not just internal R&D. The addition reflects the changing competitive landscape where emerging-market companies are no longer just manufacturing generics but developing novel therapies.

The description of compounding/counterfeit incretins shifted from "an increase in recent periods" to "we continue to see" this activity, and added "mass-compounded" as a descriptor. The change from "increase" to "continue" suggests the issue persists at elevated levels rather than accelerating further. The "mass-compounded" addition distinguishes large-scale compounding operations from traditional pharmacy compounding, clarifying the regulatory and market concern.

The EU pharmaceutical legislation progressed from draft (April 2023) to agreement-in-principle (December 2025). Lilly's tone shifted from anticipating "negative" impact "if approved as drafted" to stating the impact is "currently uncertain." This reflects the legislative process moving forward but with final details and implementation still unclear. The removal of the negative assessment may indicate the final agreement differs from the original draft or that Lilly is adopting a more neutral public stance.

The EU data protection discussion moved from uncertain proposals to a concrete agreement-in-principle in December 2025 that would reduce the base period from effectively 10 years to 8 years, with conditional incentives, and cut the maximum by one year. This represents a material change in the regulatory environment for new product launches in Europe, potentially shortening exclusivity periods and accelerating biosimilar/generic competition, which could pressure pricing and revenue for future products.

Lilly added disclosure of preliminary agreements with the U.S. government and broader U.S. policy efforts to align domestic pharmaceutical pricing with international benchmarks. This is new language describing active negotiations or policy initiatives that could pressure U.S. prices downward by referencing lower prices in countries with cost-containment systems. The disclosure acknowledges uncertainty but flags potential revenue impact across global markets, suggesting these efforts could affect both U.S. and international pricing strategies.

The 340B litigation progressed from the initial November 2024 filing to a May 2025 district court ruling against Lilly, which Lilly then appealed to the D.C. Circuit. The district court sided with HRSA, requiring preapproval of Lilly's cash replenishment model. This adverse ruling increases uncertainty around Lilly's ability to implement its preferred 340B distribution model and could sustain higher 340B-related rebate costs if the appeal is unsuccessful.

Lilly increased its R&D workforce by approximately 1,000 people (9% growth) from year-end 2024 to year-end 2025. This reflects continued investment in discovery and development capabilities to support the pipeline, particularly in cardiometabolic health, immunology, neuroscience, and oncology. The headcount expansion signals confidence in the pipeline and willingness to invest in innovation despite broader industry cost pressures.

Lilly's total workforce grew by approximately 3,000 people (6% growth) from year-end 2024 to year-end 2025, with 2,000 of the increase outside the U.S. This reflects expansion to support manufacturing scale-up (new sites), commercial operations for high-growth products (Mounjaro/Zepbound), and R&D. The international headcount growth (8%) outpaced domestic growth, consistent with global manufacturing and market expansion.

Lilly reorganized its executive leadership in 2025 with multiple role changes: Adrienne Brown, Kenneth Custer, and Carole Ho were promoted to lead Immunology, Cardiometabolic Health, and Neuroscience respectively (Ho replaced Anne White, who is no longer listed); Patrik Jonsson moved from Cardiometabolic Health/USA to International; Ilya Yuffa moved from International to USA/Global Customer Capabilities; Skovronsky's title expanded to Chief Scientific and Product Officer; and Van Naarden added Head of Corporate Business Development to his Oncology role. This reflects a significant leadership realignment, likely to support the company's growth phase and therapeutic-area focus.

The IP table for Kisunla (donanemab, Alzheimer's disease) was expanded to include major European countries with compound patent protection through 2036, in addition to the existing U.S. and Japan entries. This reflects regulatory progress in Europe; the baseline noted donanemab was submitted for EU review, and the current filing's addition of European patent dates suggests approval is anticipated or has occurred.

Total revenue increased 45% year-over-year to $65.2 billion in 2025, compared to 32% growth in the prior year. The acceleration reflects continued strong demand for Mounjaro and Zepbound, which together accounted for 56% of total revenues in 2025.

Net income nearly doubled to $20.6 billion (up 95%) and diluted EPS increased 96% to $22.95. The growth was driven by higher gross margin from favorable product mix and improved production costs, partially offset by increased R&D and marketing expenses.

The company disclosed preliminary voluntary agreements with the U.S. government announced in November 2025 to lower Medicaid and certain other drug prices and adopt a more balanced pricing approach across developed nations. The disclosure highlights execution risks, including the possibility that expanded obesity-medicine access may not generate sufficient revenue to offset pricing concessions, and warns that aligning U.S. pricing with international benchmarks could negatively impact pricing strategies, demand, access, and competitive positioning.

The company disclosed that Medicare beneficiaries will gain access to discounted Lilly obesity medicines by July 1, 2026, and state Medicaid programs will have the option to expand access. This represents a significant expansion of coverage for Zepbound and potentially orforglipron, though at discounted prices.

The company received a Commissioner's National Priority Voucher for orforglipron (an oral obesity treatment) and submitted it to the FDA under the expedited review pathway. This accelerates the regulatory timeline for a key pipeline asset that could compete with injectable incretins.

The OBBBA was enacted in July 2025, making permanent several favorable tax provisions: lower foreign income tax rates, immediate R&D expense deductibility, and 100% bonus depreciation for capital assets. These changes improve the company's tax position and cash flow from operations.

Mounjaro revenue nearly doubled to $23.0 billion (up 99%), driven by strong demand in the U.S. (up 53% to $13.7 billion) and international expansion (up to $9.3 billion from $2.6 billion). The company launched Mounjaro in all major markets internationally during 2025.

Zepbound revenue increased to $13.5 billion, driven by increased demand in the U.S., partially offset by lower realized prices. Zepbound and Mounjaro together accounted for 56% of total company revenues in 2025.

Capital expenditures increased 54% to $7.8 billion in 2025, reflecting continued investments in global manufacturing facilities to meet existing and expected demand for incretin medicines. The company expects meaningfully higher capex to continue in the near term.

Total debt increased $8.9 billion to $42.5 billion as of December 31, 2025, reflecting continued borrowing to fund capital expenditures, business development activities, and share repurchases. The company issued $6.5 billion of fixed-rate notes in February 2025.

The company repurchased $4.1 billion of shares in 2025 under the new $15.0 billion authorization, with $10.9 billion remaining. This represents a significant increase in capital return compared to $2.5 billion in 2024.

The company increased its quarterly dividend to $1.73 per share for 2026 (indicated annual rate of $6.92), up from $6.00 per share paid in 2025. This represents a 15% increase in the annual dividend rate.

The company's contract manufacturing commitments decreased from approximately $14 billion to approximately $10 billion. This likely reflects the fulfillment of certain purchase obligations as manufacturing capacity came online and production ramped up during 2025.

The company disclosed that in January 2026, HHS selected Trulicity and Verzenio for government-set prices effective in 2028, expanding the number of Lilly products subject to IRA price controls. The updated disclosure removes the specific 66% discount figure for Jardiance and the reference to accelerating revenue erosion prior to exclusivity expiry, instead stating the IRA will "meaningfully influence" business strategies.

The company added disclosure about recently imposed or aligned tariffs and trade restrictions. While pharmaceuticals are currently exempt from certain tariffs, the company warns that exemptions may be terminated and that additional restrictions could disrupt supply, increase costs, or otherwise harm the business, with limited ability to pass costs through to customers.

The disclosure shifted from describing 2024 supply constraints and current supply-demand balance to forward-looking factors affecting near-term performance (orforglipron approval timing, Medicare access, new channel uptake) and longer-term competitive sustainability. The company now emphasizes that incretin volume fluctuations can disproportionately impact results and that long-term success depends on maintaining competitive position and delivering further innovations.

The company updated its disclosure to note that the FDA confirmed in late 2024 that the tirzepatide shortage had ended and that compounding pharmacies are required to cease mass production. However, the company added language stating it "cannot guarantee adequate regulation or compliance," indicating ongoing concerns about compounded incretin products despite the FDA's shortage determination.

Research and development expenses increased 21% to $13.3 billion in 2025, compared to 18% growth in the prior year. The increase was driven by continued investments in the company's early and late-stage portfolio, including expanded Phase 3 programs for orforglipron, retatrutide, and other cardiometabolic assets.

Marketing, selling, and administrative expenses increased 29% to $11.1 billion in 2025, compared to 16% growth in the prior year. The acceleration reflects promotional efforts supporting ongoing and planned launches, particularly for incretin medicines in new markets and indications.

The effective tax rate increased to 19.8% in 2025 from 16.5% in 2024, primarily driven by unfavorable impacts related to the jurisdictional mix of earnings and U.S. tax law changes in 2025 relative to 2024. Both periods were unfavorably impacted by non-deductible acquired IPR&D charges, with a larger impact in 2024.

The company's 2025 acquired IPR&D charges of $2.9 billion (down 11% from $3.3 billion in 2024) were primarily related to acquisitions of Scorpion's PI3Kα inhibitor program and SiteOne, replacing the prior year's Morphic acquisition as the primary driver.

The company disclosed that it has entered into acquisition agreements in 2026 (subject to closing conditions) with potential amounts payable at closing of less than $3 billion. This signals continued business development activity to enhance the pipeline.

Revenue increased from $45.0B in FY2024 to $65.2B in FY2025, a 45% year-over-year increase driven by strong performance in cardiometabolic products (Mounjaro, Zepbound) and oncology (Verzenio). This growth significantly outpaced the prior-year increase of 32%.

Net income nearly doubled from $10.6B in FY2024 to $20.6B in FY2025, reflecting strong revenue growth and operating leverage. Diluted EPS increased from $11.71 to $22.95.

The company repurchased $4.1B of stock in FY2025 (4.8 million shares) compared to $2.5B in FY2024 (3.0 million shares), a 64% increase in dollar terms reflecting increased capital return to shareholders.

Sales rebates and discounts accrual increased from $11.5B at end-FY2024 to $17.4B at end-FY2025, a 51% increase reflecting higher sales volume and the mix of products subject to rebate programs (particularly Mounjaro and Zepbound).

Net property and equipment increased from $17.1B to $24.7B, a 44% increase driven by capital expenditures of $ 65,179 in FY2025 (up from $ 65,179 in FY2024) to expand manufacturing capacity for high-growth products.

Long-term debt increased from $28.5B to $40.9B, reflecting $13.2B in new debt issuances during FY2025 to fund capital expenditures, acquisitions, and working capital needs associated with rapid revenue growth.

Lilly acquired Verve Therapeutics for $549M cash plus up to $300M in milestone payments. The acquisition brought in $608M of acquired IPR&D (primarily VERVE-102, a PCSK9 editor) and $127M of goodwill, expanding Lilly's cardiovascular pipeline.

Lilly recognized a $200M sales-based milestone for Jardiance in FY2025 and has the right to receive up to $910M in additional milestones in 2026, reflecting strong commercial performance of the Jardiance product family.

Lilly disclosed new details on the Ebglyss (lebrikizumab) license agreement with Roche, including tiered royalty rates (high single digits to high teens) and up to $975M in potential sales-based milestones payable to Roche.

Lilly sublicensed European rights for Ebglyss to Almirall and will receive tiered royalties (low double digits to low twenties) plus up to $1.2B in potential sales-based milestones, providing upside from European commercialization.

Lilly disclosed a license agreement with Chugai for orforglipron (an oral GLP-1 agonist in development), under which Chugai will receive tiered royalties (mid single digits to low teens) on future sales if the product is approved.

The incretin product liability litigation expanded significantly: Zepbound was added to the list of products; the MDL split into two separate proceedings (gastrointestinal injuries and NAION claims); cases now include additional jurisdictions (Quebec, Canada); and the Georgia state court case is no longer separately mentioned.

The Seventh Circuit affirmed the adverse jury verdict in September 2025, and Lilly recognized a charge. The court denied rehearing en banc in December 2025. Lilly is now assessing next steps (likely a Supreme Court petition).

The Ninth Circuit denied Lilly's appeal of the Actos class certification in June 2025 and denied rehearing en banc in August 2025. Lilly and Takeda filed a petition for certiorari to the Supreme Court in November 2025, escalating the litigation to the highest court.

The Health Choice Alliance qui tam case expanded significantly in August 2025: the relator filed a second lawsuit in a different court, added the State of Texas as a party, and expanded the claims from three products (Humalog, Humulin, Forteo) to fifteen products. Lilly is opposing the dismissal of the first lawsuit.

The disclosure regarding the DOJ subpoena for the Branchburg, New Jersey manufacturing facility was removed from the FY2025 filing. No explanation for the removal or resolution of the matter was provided.

Advertising expenses increased from $ 65,179 in FY2024 to $ 65,179 in FY2025, more than doubling year-over-year, reflecting increased promotional spending for high-growth products like Mounjaro and Zepbound. The disclosure now states expenses are "generally" (not always) included in marketing, selling, and administrative expenses.

LLY disclosed preliminary voluntary agreements with the U.S. government to lower Medicaid and other drug prices and adopt a more balanced international pricing approach. The company flags execution risks (delays, unfavorable terms), revenue-offset uncertainty (expanded obesity-medicine access may not cover pricing concessions), and the broader risk that aligning U.S. prices with international benchmarks could pressure pricing strategies and competitive positioning globally.

LLY added disclosure that obesity-medicine access is critical to its business, that many international payers do not cover weight-loss indications (requiring patient self-pay), and that LillyDirect cash-pay sales grew materially in 2025. The company flags risks tied to patient participation levels (influenced by pricing, economic conditions, competition), potential regulatory restrictions on cash-pay channels, and uncertainty about securing reimbursement coverage over time.

LLY disclosed that HHS selected Trulicity and Verzenio for Medicare price negotiation effective 2028 (in addition to Jardiance, selected in 2023 for 2026). The company expects further selections in future years, accelerating revenue erosion for major products.

LLY disclosed that CVS Caremark removed Zepbound from preferred formulary status on certain plans in July 2025, negatively impacting patient access. This is a concrete example of PBM formulary pressure on a major product.

LLY's top-six products now account for 82% of total revenue (up from 75% in 2024), and Mounjaro + Zepbound alone account for 56% (up from 48% for Mounjaro + Trulicity + Zepbound in 2024). The product order changed (Zepbound moved up, Trulicity moved down), reflecting the rapid growth of the incretin franchise and increasing revenue concentration risk.

LLY updated the counterfeit/compounded-incretin disclosure from "have seen an increase" to "continue to see" (ongoing issue), added "mass-compounded" as a distinct category, and expanded the harm description to include improper commercialization practices that condition consumer expectations and disadvantage compliant market participants (beyond patient safety alone).

LLY added orforglipron as an example of a highly anticipated product candidate under regulatory review, signaling investor focus on this oral GLP-1 agonist.

LLY updated the tariff disclosure from "February 2025" (future-tense in the baseline) to "2025" (past-tense in the current), confirming the tariffs were imposed. The company also broadened the scope from specific jurisdictions (Mexico, Canada, Europe) to "a variety of other geographies" and added explicit language about supply disruptions, cost increases, and retaliatory measures.

LLY expanded the 340B disclosure to emphasize that the program's expansion and entity growth (including through state contract-pharmacy mandates) impact revenue on an increasing percentage of sales, and added that Medicaid rebate-calculation changes could further increase 340B obligations. The tone shifted from describing state legislation as subject to legal challenges to describing the revenue impact as ongoing and growing.

LLY added explicit language that AI investments may not enhance products, services, efficiency, or profitability, and that there are "significant risks" in developing and deploying AI. The baseline only mentioned exacerbation of other risks; the current filing adds uncertainty about AI's business value.

LLY added a cross-reference to the voluntary U.S. pricing agreements (disclosed earlier in the risk factors) and noted that U.S. efforts to align domestic pricing with international benchmarks may pressure international payers, creating competing pricing objectives with uncertain outcomes.

LLY restructured the supply-chain risk disclosure to lead with "external environmental factors" and added tariffs as the first factor (previously not listed separately). The company also enumerated seven categories of external factors (tariffs, cost inflation, labor, natural disasters, pandemics, economic downturns, geopolitical tensions) in a more structured format, emphasizing tariffs as a distinct and leading risk.

LLY added disclosure that some 2025 tariffs have been paused but may resume quickly, and that pharmaceutical exemptions from certain tariffs may be terminated or may not apply to future tariffs, creating uncertainty about cost impacts.

LLY added explicit language that the company may not be able to offset tariff-related cost increases to any meaningful degree, due to pharmaceutical regulation and commercialization constraints (e.g., price controls, reimbursement dynamics).

LLY added language that technological innovation (including AI, per earlier disclosure) is amplifying competitive dynamics by enabling broader participation in drug discovery and new delivery models, and that the company's business practices may not prove sufficient to compete effectively.

LLY added that counterfeit and mass-compounded incretin actors may condition consumer expectations or disadvantage compliant market participants (beyond patient safety alone), framing the harm as competitive and reputational, not just safety-related.